US Stock MarketDetailed Quotes

EWTX Edgewise Therapeutics

Watchlist
  • 32.370
  • +0.420+1.31%
Trading Nov 21 14:06 ET
3.07BMarket Cap-21580P/E (TTM)

About Edgewise Therapeutics Company

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Company Profile

SymbolEWTX
Company NameEdgewise Therapeutics
Listing DateMar 26, 2021
Issue Price16.00
Founded2017
CEODr. Kevin Koch, PhD
MarketNASDAQ
Employees88
Fiscal Year Ends12-31
Address1715 38th Street
CityBoulder
ProvinceColorado
CountryUnited States of America
Zip Code80301
Phone1-720-262-7002

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Kevin Koch, PhD
  • President, Chief Executive Officer and Director
  • 3.98M
  • R. Michael Carruthers
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Joanne M. Donovan, M.D.,PhD
  • Chief Medical Officer
  • 1.72M
  • Dr. Marc Semigran, M.D.
  • Chief Development Officer
  • --
  • Dr. Behrad Derakhshan, PhD
  • Chief Business Officer
  • 1.76M
  • Dr. Alan Russell, PhD
  • Chief Scientific Officer and Director
  • --
  • Dr. Peter Thompson, M.D.
  • Chairman of the Board
  • 226.00K
  • Laura A. Brege
  • Independent Director
  • 208.00K
  • Dr. Jonathan D. Root,M.D.
  • Independent Director
  • 199.50K
  • Dr. Badreddin Edris, PhD
  • Independent Director
  • 193.00K
  • Dr. Jonathan C. Fox, F.A.C.C.,M.D.,PhD
  • Independent Director
  • 485.00K
  • Arlene M. Morris
  • Independent Director
  • --
  • John R. Moore
  • General Counsel and Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data